Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6551
    +0.0027 (+0.42%)
     

  • OIL

    84.02
    +0.45 (+0.54%)
     

  • GOLD

    2,359.00
    +16.50 (+0.70%)
     

  • Bitcoin AUD

    98,311.43
    +510.83 (+0.52%)
     

  • CMC Crypto 200

    1,387.74
    -8.79 (-0.63%)
     

  • AUD/EUR

    0.6097
    +0.0024 (+0.40%)
     

  • AUD/NZD

    1.0981
    +0.0023 (+0.21%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,122.25
    +43.39 (+0.54%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,029.04
    +111.76 (+0.62%)
     

  • Hang Seng

    17,666.43
    +381.89 (+2.21%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

HTG Announces Board of Directors Transition

HTG Molecular Diagnostics, Inc.
·1-min read

Timothy Johnson to Retire from the Board; Ann Hanham, Ph.D. Remains Lead Independent Director

TUCSON, Ariz., Jan. 19, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that Timothy (TJ) B. Johnson has resigned his positions as Executive Chairman and a member of HTG’s Board of Directors. Ann F. Hanham, Ph.D. will remain as Lead Independent Director.

Mr. Johnson has served as HTG’s Executive Chairman since March 31, 2019 and as a member of the Company’s Board of Directors since January 2008. Mr. Johnson previously served as the Company’s Chief Executive Officer from January 2008 until his transition to Executive Chairman in March 2019.

“TJ has been a cornerstone of HTG since 2008. During this time, he has been a passionate advocate for HTG and its mission to advance precision medicine,” said Mr. Lubniewski. “We are grateful for the valuable contributions TJ made to HTG over the years and wish him continued success.”

ADVERTISEMENT

About HTG:
HTG is focused on NGS-based molecular profiling. The Company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.

Contact:
Ashley R. Robinson
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com